Vioxx (rofecoxib) was a prescription painkiller and anti-inflammatory drug used to treat arthritis, acute pain, menstrual cramps, and migraines. It was one of the most widely prescribed medications of its era before manufacturer Merck voluntarily pulled it from the worldwide market on September 30, 2004, after a clinical trial revealed it increased the risk of heart attacks and strokes.
FDA-Approved Uses
Vioxx carried six official indications from the FDA:
- Osteoarthritis: Relief of joint pain, stiffness, and swelling caused by cartilage breakdown, its most common use.
- Rheumatoid arthritis in adults: Managing the chronic joint inflammation and pain of this autoimmune condition.
- Juvenile rheumatoid arthritis: Approved for children age 2 and older who weighed at least 22 pounds.
- Acute pain in adults: Short-term relief from pain after dental procedures, injuries, or surgery.
- Primary dysmenorrhea: Treatment of menstrual cramps.
- Migraine attacks: Acute treatment of migraines with or without aura in adults.
Osteoarthritis and rheumatoid arthritis were by far the most common reasons doctors prescribed it. Millions of people with chronic joint pain took Vioxx daily, often for months or years at a time.
How Vioxx Worked
Vioxx belonged to a class called COX-2 selective inhibitors. Your body produces two versions of an enzyme called cyclooxygenase: COX-1 and COX-2. COX-2 drives inflammation and pain, while COX-1 helps protect the stomach lining. Traditional painkillers like ibuprofen and naproxen block both enzymes, which is why they can cause stomach ulcers and gastrointestinal bleeding with long-term use.
Vioxx was designed to block only COX-2, delivering the same pain relief with far less stomach damage. That was its major selling point, and it was a real advantage for patients who needed daily pain relief but had a history of stomach problems. For menstrual pain specifically, clinical trials showed that a single dose of Vioxx performed similarly to ibuprofen or naproxen sodium in reducing cramps.
Why It Was Withdrawn
The withdrawal traces back to a study that had nothing to do with arthritis. In the APPROVe trial, researchers were testing whether Vioxx could prevent the recurrence of colon polyps. Participants took 25 mg daily or a placebo. The trial was stopped early when data showed that patients on Vioxx had a significantly increased risk of serious cardiovascular events, including heart attacks and strokes, beginning after about 18 months of continuous use.
Warning signs had appeared earlier. The VIGOR study, published in 2000, compared Vioxx to naproxen in rheumatoid arthritis patients and found that those taking Vioxx experienced roughly four to five times as many heart attacks. At the time, Merck and some researchers argued this gap existed because naproxen was protecting the heart, not because Vioxx was causing harm. The APPROVe trial, which used a placebo instead of naproxen, settled the question: the problem was Vioxx itself.
Merck pulled Vioxx from shelves worldwide on September 30, 2004. By that point, an estimated 80 million people had taken the drug. The withdrawal triggered one of the largest pharmaceutical litigation events in history.
What Replaced Vioxx
After Vioxx was removed, a second COX-2 inhibitor called Bextra (valdecoxib) was also pulled from the market in April 2005 at the FDA’s request. Today, only one COX-2 selective drug remains available: Celebrex (celecoxib). It carries a boxed warning about cardiovascular risk, as do all prescription NSAIDs now on the market.
The Vioxx withdrawal reshaped how regulators and doctors think about the entire class of anti-inflammatory drugs. The FDA required every prescription NSAID, whether COX-2 selective or not, to add a boxed warning highlighting both cardiovascular risk and the potential for serious gastrointestinal bleeding. That includes common drugs like prescription-strength ibuprofen, naproxen, diclofenac, meloxicam, and indomethacin.
For patients who had been taking Vioxx for arthritis, the transition typically meant switching to Celebrex, a traditional NSAID (sometimes paired with a stomach-protecting medication), or a non-drug approach like physical therapy. The general guidance that emerged from the Vioxx era still holds: use the lowest effective dose of any NSAID for the shortest time needed.